Water vapour therapy
- Moderate-to-severe LUTS were significantly improved within ≤3 months after thermal therapy and remained consistently durable through 4 years.1
- Rezūm™ System is considered a minimally invasive alternative for men with moderate-to-severe BPH who do not want to rely on pharmaceutical management of their symptoms. 2
- The advanced technology can empower urologists to achieve significant clinical improvements and deliver an impactful, durable response for their patients.3
- Effective symptom relief and improved quality of life remained durable throughout four years using Rezūm. 4
- Rezūm has a minimal physician learning curve, and early intervention may be a more ideal option for men, rather than pharmaceutical agents or invasive surgery.5
- Thermal therapy improve symptom scores by approximately 50% throughout 36 months (p <0.0001).6
- A single water vapour thermal therapy procedure provided effective and durable improvements in symptom scores with lower observed clinical progression rates compared to daily long-term use of pharmaceutical agents.7
- Convective water vapour thermal therapy provides sustainable improvements for 12 months to lower urinary tract symptoms and urinary flow while preserving erectile and ejaculatory functions.8
- Identification of treatments for LUTS/BPH that demonstrate cost-effectiveness and provide appreciable symptom relief is paramount as reimbursement for patient care moves from volume-based services to value based services.9, 10
Download further academic publications about water vapour therapy
- McVary KT, Roehrborn C. Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Late-Breaking Abstract. J Urol. 2020 Apr;203(4):e1021.
- Rezūm™ water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study
- Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial
- Laser therapy has proven to have shorter catheterisation and hospitalisation times compared with TURP1
- Photoselective vaporisation of the prostate (PVP) using the GreenLight XPS™ -180 W laser system can be considered a safe and durable procedure for patients with BPH needing surgical treatment, with effectiveness maintained for a period of at least 5 years.2
- The GreenLight XPS laser system has advanced technical specifications compared to previous devices, with a maximum power of 180 W and an improved beam geometry of the MoXy ™ fibre.3
- PVP decreased the prostate-specific antigen (PSA) level significantly (a reduction of 56%) from 4.5 ng/mL preoperatively to 2.6 ng/mL at 57 months 4
- The long-term patient satisfaction is high with PVP - 80% (74/84) of the patients were at least mostly satisfied after 57 months5
- Both PVP and GreenLEP are considered safe and effective for the surgical management of benign prostatic obstruction in patients with large prostate volumes (>80 mL), resulting in satisfactory short-term (6-month) functional outcomes.6
Download further academic publications about laser therapy:
- Photoselective vaporization of the prostate with the 180-W XPS-GreenLight laser: Five-year experience of safety, efficiency, and functional outcomes
- Long-term patient-reported clinical outcomes and reoperation rate after photovaporization with the XPS-180W GreenLight Laser
- Direct comparison of Green Light Laser XPS Photoselective Vaporization of the Prostate (PVP) and Green Laser En Bloc enucleation of the prostate (GreenLEP) in enlarged glands >80 ml: A study of 120 patients
- Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: a comparison between GreenLight 532‑nm and holmium lasers
EAU, AUA and NICE guidelines
NEW NICE publishes positive guidance on Rezūm Water Vapour Therapy supporting the case for adopting this minimally invasive BPH treatment in the NHS.
The European Association of Urology (EAU) and the American Urological Association (AUA) regularly publish a reference on effective, evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). These references will provide you with a general recommendation on therapy methods that are considered recognised and safe.
GreenLightTM, AurigaTM XL and RezūmTM are included in the AUA guidelines.
(Last updated on July 1, 2019)
In addition, the National Institute for Health and Care Excellence (NICE), a non-departmental public body that provides guidance and advice to improve health and social care in England, has provided guidance on vapour therapy, GreenLightand Auriga XL.
NICE also has recently provided positive guidance on Rezūm Water Vapour Therapy supporting the case for adopting this minimally invasive BPH treatment in the NHS.
The BPH decision tree
Through a simple list of yes & no questions, the BPH decision tree has been developed to help during the decision-making process.17